A 62-year-old man with Parkinson disease (PD) on levodopa monotherapy for 5 years presents with motor fluctuations and "on-off" episodes. He experiences predictable end-of-dose deterioration lasting 30–45 minutes before each dose. Examination confirms bradykinesia, rigidity, and postural instability during "off" periods. What is the most appropriate next step in management?

Explanation

## Clinical Context: Motor Fluctuations in Advanced PD This patient exhibits **end-of-dose deterioration** — a hallmark of motor fluctuations that emerges after prolonged levodopa therapy. The predictable timing (30–45 min before next dose) indicates that the duration of levodopa's effect is shortening, likely due to progressive nigrostriatal denervation and loss of dopamine buffering capacity. ## Pathophysiology of Motor Fluctuations **Key Point:** Motor fluctuations arise because: 1. Surviving dopaminergic neurons lose capacity to store and buffer dopamine 2. Levodopa's pharmacokinetic half-life (~60–90 min) becomes rate-limiting 3. Pulsatile dopaminergic stimulation triggers dyskinesias and "on-off" cycling ## Management Strategy for End-of-Dose Deterioration **High-Yield:** The standard approach is to **extend the duration of dopaminergic effect** rather than simply increase levodopa dose: | Intervention | Mechanism | Timing | |---|---|---| | **COMT inhibitor** (entacapone, tolcapone) | Blocks catechol-O-methyltransferase; prolongs levodopa half-life by ~30% | First-line adjunct | | **Dopamine agonist** (pramipexole, ropinirole) | Direct D2/D3 receptor agonism; non-pulsatile stimulation | First-line adjunct | | **MAO-B inhibitor** (selegiline, rasagiline) | Slows dopamine catabolism; modest effect on fluctuations | Adjunctive | | **Increase levodopa dose** | Raises peak levels but shortens duration further | Not recommended alone | | **Apomorphine infusion** | Continuous subcutaneous dopaminergic stimulation | Reserved for severe, refractory fluctuations | **Clinical Pearl:** Adding a COMT inhibitor or dopamine agonist is the **first-line strategy** for predictable end-of-dose deterioration. Both reduce "off" time and allow levodopa dose reduction in many patients. Apomorphine is reserved for patients who fail oral/transdermal options or have severe, unpredictable fluctuations. ## Why This Patient Needs Adjunctive Therapy **Key Point:** Simply increasing levodopa dose will: - Raise peak levels (worsening dyskinesias) - Further shorten duration of effect (worsening "off" periods) - Accelerate motor complications Extending the **duration** of dopaminergic effect is the correct principle. ## Recommended Next Step 1. Add **entacapone 200 mg** with each levodopa dose (COMT inhibitor), OR 2. Initiate a **dopamine agonist** (e.g., pramipexole 0.5–1 mg TID or ropinirole 1–2 mg TID) 3. Consider combination therapy if monotherapy adjunct is insufficient 4. Reassess in 2–4 weeks; reduce levodopa dose if dyskinesias emerge [cite:Harrison 21e Ch 427]